Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2018

  • ID: 4592424
  • Report
  • 67 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Almirall SA
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • MORE
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2018, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights:

This latest pipeline guide Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 2, 2, 1 and 2 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall SA
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • MORE
Introduction

Report Coverage

Onychomycosis (Tinea Unguium) - Overview

Onychomycosis (Tinea Unguium) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Onychomycosis (Tinea Unguium) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development

Almirall SA

Blueberry Therapeutics Ltd

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Moberg Pharma AB

NAL Pharmaceuticals Ltd

Novabiotics Ltd

Novan Inc

Viamet Pharmaceuticals Inc

Onychomycosis (Tinea Unguium) - Drug Profiles

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-0305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Onychomycosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELS-160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HXP-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ME-1111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NORS-0791 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-3058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Onychomycosis (Tinea Unguium) - Dormant Projects

Onychomycosis (Tinea Unguium) - Discontinued Products

Onychomycosis (Tinea Unguium) - Product Development Milestones

Featured News & Press Releases

May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment

Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-

Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-

Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting

Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases

Apr 12, 2017: Novan Reports Positive Top line Results with SB208 in Phase 2 Trial

Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting

Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting

Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial

Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis

Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada

Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting

Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H2 2018

Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H2 2018

Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2018

Onychomycosis (Tinea Unguium) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Onychomycosis (Tinea Unguium) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Almirall SA
  • Blueberry Therapeutics Ltd
  • Hexima Ltd
  • Kaken Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Viamet Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll